Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Relapsing Multiple Sclerosis (RMS)

Tundra lists 4 Relapsing Multiple Sclerosis (RMS) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT04130997

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

Gender: All

Ages: 18 Years - Any

Updated: 2026-04-08

14 states

Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING

NCT06869785

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.

Gender: All

Ages: 18 Years - 100 Years

Updated: 2026-03-20

24 states

Relapsing Multiple Sclerosis (RMS)
RECRUITING

NCT06486779

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)

Gender: All

Ages: 18 Years - 55 Years

Updated: 2025-12-24

Relapsing Multiple Sclerosis (RMS)
NOT YET RECRUITING

NCT07006805

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis

Gender: All

Ages: 18 Years - 60 Years

Updated: 2025-10-31

Relapsing Multiple Sclerosis (RMS)
Progressive Multiple Sclerosis (PMS)
Multiple Sclerosis - Relapsing Remitting
+4